PathAI

PathAI is an AI-driven digital pathology company providing cloud-native software solutions for anatomic pathology laboratories, biopharma organizations, and clinical research. The company specializes in AI-powered histopathology analysis and digital pathology workflow management. PathAI's flagship platform, AISight®, is a cloud-native, open-architecture enterprise solution that integrates case management, image management, and AI-based diagnostic tools to enable multiple histopathology use cases. The platform serves as a central hub for digital pathology workflows across academic medical centers, reference laboratories, and health systems. AISight® Dx received FDA clearance for primary diagnosis in June 2025. PathAI also offers specialized AI-assisted tools including AIM-MASH (FDA-qualified for metabolic-associated fatty liver disease clinical trials) and AIM-HI UC/IBDExplore for standardized histopathology endpoints in clinical trials. The company operates a proprietary pathologist contributor network of board-certified pathologists to support algorithm training and validation, with millions of annotations contributed. Services include BioPharma solutions for drug and diagnostic development, central laboratory operations, and anatomic pathology lab solutions. Notable partnerships include expanded collaboration with Labcorp to deploy FDA-cleared digital pathology nationwide. The company combines pathology domain expertise with machine learning to advance precision medicine, biomarker discovery, and clinical trial standardization.